The MLST8 antibody is a research tool used to detect MLST8 (mammalian lethal with SEC13 protein 8), also known as GβL (G protein beta subunit-like), a key regulatory component of the mechanistic target of rapamycin (mTOR) signaling pathway. MLST8 is a conserved protein that forms part of both mTOR complex 1 (mTORC1) and mTORC2. which regulate cell growth, proliferation, metabolism, and survival in response to nutrients, growth factors, and stress. As a scaffolding protein, MLST8 stabilizes mTOR interactions within these complexes and modulates their kinase activity. Antibodies targeting MLST8 are widely used in molecular biology and cancer research to study mTOR pathway dynamics, protein-protein interactions, and subcellular localization via techniques like Western blotting, immunoprecipitation, and immunofluorescence. Dysregulation of MLST8 has been implicated in diseases such as cancer, diabetes, and neurological disorders, making it a focus for therapeutic development. These antibodies help elucidate MLST8's role in mTOR-related pathologies, assess its expression levels in tissues or cell lines, and evaluate the efficacy of mTOR inhibitors in preclinical studies. Validation of MLST8 antibodies ensures specificity for distinguishing between mTORC1 and mTORC2-associated functions.